| __timestamp | BioCryst Pharmaceuticals, Inc. | Catalyst Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7461000 | 4473654 |
| Thursday, January 1, 2015 | 13047000 | 8597010 |
| Friday, January 1, 2016 | 11253000 | 7910260 |
| Sunday, January 1, 2017 | 13933000 | 7304399 |
| Monday, January 1, 2018 | 29514000 | 15875961 |
| Tuesday, January 1, 2019 | 37121000 | 36881187 |
| Wednesday, January 1, 2020 | 67929000 | 44233754 |
| Friday, January 1, 2021 | 118818000 | 49628000 |
| Saturday, January 1, 2022 | 159371000 | 58183000 |
| Sunday, January 1, 2023 | 213894000 | 133710000 |
Igniting the spark of knowledge
In the competitive world of biopharmaceuticals, managing operational costs is crucial for success. Over the past decade, BioCryst Pharmaceuticals, Inc. and Catalyst Pharmaceuticals, Inc. have demonstrated contrasting strategies in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, BioCryst's SG&A expenses surged by nearly 2,800%, peaking at $213 million in 2023. This reflects their aggressive expansion and investment in administrative capabilities. In contrast, Catalyst Pharmaceuticals maintained a more conservative growth, with SG&A expenses increasing by approximately 2,900% to $134 million in the same period. This strategic restraint may indicate a focus on operational efficiency and cost management. As these companies navigate the evolving pharmaceutical landscape, their SG&A strategies will be pivotal in determining their competitive edge and financial health.
Operational Costs Compared: SG&A Analysis of AbbVie Inc. and Catalyst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing United Therapeutics Corporation and Catalyst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Viatris Inc. and BioCryst Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Summit Therapeutics Inc. or Catalyst Pharmaceuticals, Inc.
Walgreens Boots Alliance, Inc. and Catalyst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Exelixis, Inc. vs BioCryst Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of ACADIA Pharmaceuticals Inc. and BioCryst Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Catalyst Pharmaceuticals, Inc. and HUTCHMED (China) Limited
Who Optimizes SG&A Costs Better? Catalyst Pharmaceuticals, Inc. or Wave Life Sciences Ltd.
SG&A Efficiency Analysis: Comparing Arrowhead Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.
ImmunityBio, Inc. vs BioCryst Pharmaceuticals, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Travere Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.